Skip to main content

Table 2 Best tumor response

From: Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

 

Arm A

Arm B

 

n

(%)

n

(%)

Partial response

7

(20)

6

(18)

No change

12

(34)

12

(35)

Progressive disease

16

(46)

16

(47)

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us